Specifically, they discovered an unexpected phenomenon in which EGFR inhibitors decreased the number of tumor cells with high levels of EGFRvIII in vitro and in vivo, and after drug removal, the tumor cells containing a high copy number of EGFRvIII returned, which exceeded the classical genetics. The gene discussed is EGFR; the disease is neoplasm.